Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated July 22, 2002, serves as an erratum and announcement regarding the company's first-half 2002 financial results. The filing corrects the scheduled time for the upcoming conference call and announces a significant regulatory milestone for the product Elitek (rasburicase).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the first half of 2002. These figures are expected to be disclosed during the conference call scheduled for July 24, 2002.
Material Changes and Regulatory Developments
- Conference Call Schedule Change: The time for the 2002 first-half sales conference call was changed from 3:00 p.m. to 12:00 p.m. (Paris time) on Wednesday, July 24, 2002.
- FDA Approval: The U.S. Food and Drug Administration (FDA) approved Elitek (rasburicase) for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies receiving anti-cancer therapy.
- Product Launch: Elitek is expected to be commercially available in the U.S. in August 2002. The product was previously launched in Europe as Fasturtec in the first half of 2001.
Guidance, Outlook, and Risks
Outlook: Management projects that worldwide sales of Fasturtec/Elitek should reach EUR 100 million in 2005.
Risks and Contingencies: The filing highlights specific safety risks associated with Elitek:
- Contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of severe hemolysis.
- Potential for severe hypersensitivity reactions, including anaphylaxis.
- Association with methemoglobinemia.
Investor Verification Checklist
- Verify the actual first-half 2002 sales figures and profit margins during the July 24, 2002, conference call.
- Confirm the commercial launch date of Elitek in the U.S. (anticipated August 2002).
- Monitor the sales trajectory of Elitek/Fasturtec against the EUR 100 million 2005 target.
- Review the adverse event reporting for Elitek post-launch, specifically regarding G6PD deficiency screening and hypersensitivity reactions.